Sunday 18 October 2026
Export BDTX’s income statement to Excel — free account
Black Diamond Therapeutics, Inc.
BDTX Healthcare Biotechnology
Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million. In the quarter to June 2026, EPS grew 10.5% and free cash flow grew 12.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.72
0.02
−1.15%
Follow BDTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (37.21%) | (35.16%) | 22.88% | 19.23% |
+8 more TTM periods Free account |
|
| (29.21%) | (27.95%) | 16.84% | 14.54% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(42.61%) | (39.73%) | 19.11% | 17.26% | |
Free Cash Flow per Share |
(0.57) | (0.59) | 0.52 | 0.38 | |
Free Cash Flow |
(32.84) | (34.03) | 29.64 | 21.38 | |
Capital Expenditures |
— | — | 0.03 | 0.03 | |
| Other line items | |||||
Cash ROIC |
(15.89%) | (15.29%) | 12.31% | 8.17% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.77 | 0.79 | 1.32 | 0.99 | |
Depreciation/Fixed assets |
0.67 | 0.78 | 0.89 | 0.31 | |
Capex/Depreciation |
0.00 | 0.00 | 0.08 | 0.09 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.57) | (0.59) | 0.52 | 0.38 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates